Trial Profile
Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2017
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms RIOPRED
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 06 Apr 2017 Status changed from recruiting to completed.
- 28 Jan 2016 Accrual to date is 81% according to United Kingdom Clinical Research Network record